NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)
ID: 359942Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359942

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-447.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)." This initiative invites applications to leverage the NHLBI-funded TransOmics for Precision Medicine (TOPMed) program to generate integrated genetic and multi-omics data aimed at uncovering the molecular mechanisms underlying Heart, Lung, Blood, and Sleep (HLBS) disorders. The program is significant for advancing the understanding of genetic factors contributing to HLBS diseases, with a focus on transitioning from genetic associations to molecular insights, potentially utilizing artificial intelligence and machine learning tools. No direct funding will be provided; instead, successful applicants will gain access to omics assay resources and are expected to contribute data to public NIH-designated controlled-access databases. The application period opens on October 6, 2025, and closes on May 8, 2028, with a maximum project duration of three years. Interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-447-Full-Announcement.html
    PAR-25-447.html
    The Department of Health and Human Services is reissuing a Notice of Funding Opportunity (NOFO) PAR-25-447 for the NHLBI TOPMed program, titled “Omics Phenotypes of Heart, Lung, and Blood Disorders.” This X01 Resource Access Award invites applications to utilize TOPMed's capacity to generate integrated genetic and multi-omics data to uncover the molecular mechanisms of Heart, Lung, Blood, and Sleep (HLBS) disorders. No direct funding will be provided; instead, successful applicants will gain access to omics assay resources and contribute data to public NIH-designated controlled-access databases like dbGaP and NHLBI’s BioData Catalyst. The goal is to advance understanding from genetic associations to molecular and cellular contributions to HLBS diseases, potentially leveraging AI and ML. Key dates include an open date of October 6, 2025, and an expiration date of May 9, 2028. Up to 10 projects are anticipated to be approved, with a maximum project period of three years. Eligible applicants include various organizations, including foreign entities, but applications involving foreign subawards/subcontracts are not allowed. Review criteria emphasize scientific merit, the potential to enrich existing TOPMed datasets, and robust data-sharing plans.
    Similar Opportunities
    NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) for the NHLBI TOPMed program, aimed at generating integrated genetic and multi-omics data to advance the understanding of Heart, Lung, Blood, and Sleep (HLBS) disorders. This initiative seeks to transition from cataloging genetic associations to elucidating the molecular mechanisms underlying HLBS diseases, with potential applications of artificial intelligence and machine learning to enhance functional genomics research. While no funding will be provided at this time, interested small businesses are encouraged to begin forming collaborations and developing projects in anticipation of the opportunity, which is expected to be formally announced in August 2025, with applications due by October 2025. For further inquiries, potential applicants can contact the Division of Blood Diseases and Resources at NHLBI via email at nhlbidbdrgrantresource@nhlbi.nih.gov.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders," aimed at supporting investigator-initiated Phase I clinical trials for heart, lung, blood, and sleep (HLBS) disorders in both adults and children. This grant (R61/R33) facilitates funding for essential preclinical activities and the execution of clinical trials, structured in two phases: the R61 phase focuses on preparatory tasks, while the R33 phase involves the actual trial conduct, guided by specific milestones. This initiative is crucial for advancing research that addresses significant health challenges associated with HLBS disorders. Interested applicants can submit proposals starting January 3, 2025, with a maximum project period of five years, and should direct inquiries to grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-026.html.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity aimed at supporting Phase I clinical trials for therapeutic and diagnostic interventions related to heart, lung, blood, and sleep (HLBS) disorders. This initiative seeks to accelerate the development of clinical interventions by funding investigator-initiated studies that demonstrate potential advancements in HLBS health, with a focus on ensuring that applicants are prepared to initiate trials promptly after receiving funding. The funding is capped at $1.5 million per year for a project period of up to three years, contingent on satisfactory progress and milestone completion, with applications opening on January 3, 2025, and the first due date set for February 3, 2025. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-025.html.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity (FON: PAR-24-173) aimed at supporting Phase I clinical trials for therapeutics and diagnostics related to heart, lung, blood, and sleep (HLBS) disorders in both adults and children. This initiative utilizes a bi-phasic R61/R33 award mechanism, where the R61 phase focuses on preparatory activities such as finalizing trial protocols and gathering preclinical data, while the R33 phase is dedicated to executing the clinical trial. The funding limits include up to $250,000 annually for the R61 phase and $1,515,000 for the R33 phase, with total support available for a maximum of five years. Interested applicants must adhere to NIH guidelines and submit their proposals by January 7, 2027, to be considered for this opportunity. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NHLBI Program Project Applications (P01 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity for Program Project (P01) grant applications aimed at advancing research in heart, lung, and blood diseases. Applicants are required to submit proposals that include a minimum of three interrelated research projects focused on a common biomedical theme, with the option to incorporate clinical trials. This initiative is designed to foster collaborative research efforts and encourage innovative scientific directions, particularly supporting projects led by Early Stage Investigators (ESIs). The maximum funding for awarded projects is capped at $1.515 million annually, or $1.765 million if an ESI-led project is included, with a project duration of up to five years. Interested applicants can find more information and submit their proposals electronically via Grants.gov, with a closing date for applications set for September 25, 2026. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Omics Phenotypes Related to Down Syndrome for the INCLUDE Project (X01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Omics Phenotypes Related to Down Syndrome for the INCLUDE Project (X01 Clinical Trial Not Allowed)." This initiative invites applications to utilize existing biospecimens to generate integrated genomic and multi-omics data aimed at uncovering the molecular mechanisms associated with health conditions related to Down syndrome. The program emphasizes the importance of including cohorts from underrepresented racial and ethnic groups and does not provide direct funding; instead, it facilitates access to sequencing resources for various genomic profiling techniques. Interested applicants should note that the earliest submission date is February 13, 2024, and they can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-081.html.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NHLBI Early Phase Clinical Trials (R33), aimed at supporting investigator-initiated Phase I clinical trials for therapeutic and diagnostic interventions targeting heart, lung, blood, and sleep (HLBS) disorders. Applicants are required to be prepared to initiate their clinical trials within the first quarter of the project period and must demonstrate readiness in obtaining necessary regulatory approvals, including FDA and IRB, prior to the award. This funding is crucial for addressing unmet medical needs through innovative research, with a maximum budget of $1.515 million per year and a project duration of up to three years, contingent upon achieving specific milestones. Interested applicants should note the application deadline of June 4, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov for further details.
    Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), is offering a funding opportunity titled "Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)." This grant aims to support the development and validation of innovative technologies that address significant gaps in heart, lung, blood, and sleep (HLBS) research, focusing on advancing diagnostic and therapeutic solutions with promising preliminary data. Eligible applicants include a wide range of institutions and organizations, with a budget ceiling of $350,000 in direct costs per year, and total funding commitments expected to reach $2,156,000 annually for the next three fiscal years. The application deadline is set for January 11, 2025, and further details can be found on the NIH grants website or by contacting NIH Grants Information at grantsinfo@nih.gov.
    NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Trial Pilot Studies (R34 Clinical Trial Optional) through the National Heart, Lung, and Blood Institute (NHLBI). This initiative aims to support research that provides essential information for the design of future Phase II-IV clinical trials focused on heart, lung, blood, and sleep disorders, requiring applicants to demonstrate the scientific necessity and sufficiency of their proposed studies. The NHLBI emphasizes inclusivity by mandating a Plan for Enhancing Diverse Perspectives (PEDP) to enhance the project's scientific merit, with a budget of up to $450,000 in direct costs available over a maximum project period of three years. Interested applicants should note that the application period opens on January 16, 2025, and the final submission deadline is January 7, 2027; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.
    Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity for exploratory R21 grant applications focused on secondary analyses of existing human datasets related to heart, lung, blood diseases, and sleep disorders. The objective of this grant is to stimulate innovative research by utilizing existing datasets to explore novel scientific ideas and develop impactful biomedical tools and technologies, without the need for new primary data collection. This initiative is crucial for advancing public health research aligned with NHLBI priorities, with an annual funding commitment of up to $2,187,000 over three years, supporting approximately eighteen new awards each year, with a maximum of $75,000 in direct costs per application for a two-year project period. Interested applicants can find more information and application guidelines at NIH Grants, and should note that the application deadline is January 7, 2026.